Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
AbbVie | Adalimumab | Humira |  | 2003-09-08 | $11,935 M | Q3/23-Q2/24 |
Amgen | Adalimumab | Amgevita |  | 2017-03-21 |  |  |
Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-11-10 |  |  |
Bristol Myers Squibb | Abatacept | Orencia |  | 2007-05-21 | $3,667 M | Q4/23-Q3/24 |
Celltrion | Adalimumab | Yuflyma |  | 2021-02-11 |  |  |
Fresenius Kabi | Adalimumab | Idacio |  | 2019-04-02 |  |  |
Adalimumab | Kromeya |  | 2019-04-02 |  |  | |
Tocilizumab | Tyenne |  | 2023-09-15 |  |  | |
Hisamitsu Pharmaceutical | Menthol, Methyl salicylate | Salonpas | 2027-08-01 | 2008-02-20 |  |  |
Nordic Pharma | Methotrexate | Nordimet |  | 2016-08-18 |  |  |
Novartis | Canakinumab | Ilaris |  | 2009-10-23 | $1,206 M | Q2/21-Q2/24 |
Pfizer | Adalimumab | Amsparity |  | 2020-02-13 |  |  |
Etanercept | Enbrel |  | 2000-02-02 | $830 M | Y2023 |